Expression of Y-box-binding protein YB-1 allows stratification into long-and short-term survivors of head and neck cancer patients

British Journal of Cancer

Volumn 105, Issue 12, 2011, Pages 1864-1873

  Kolk, A ^a   Jubitz, N ^a   Mengele, K ^a   Mantwill, K ^a   Bissinger, O ^a   Schmitt, M ^a   Kremer, M ^b   Holm, P S ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c XVir Therapeutics GmbH   (Germany)

Author keywords

Disease specific survival; HNSCC; Prognosis; Stratification; YB 1

Indexed keywords

Y BOX BINDING PROTEIN 1; TUMOR MARKER; YBX1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONG TERM SURVIVAL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SHORT TERM SURVIVAL; SURVIVAL PREDICTION; SURVIVAL TIME; TUMOR GROWTH; CASE CONTROL STUDY; HEAD AND NECK TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SQUAMOUS CELL CARCINOMA; SURVIVOR; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SURVIVORS; TUMOR MARKERS, BIOLOGICAL; Y-BOX-BINDING PROTEIN 1;

EID: 84856011521     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.491     Document Type: Article

References (66)

1. Allum WH Stenning SP, Bancewicz J, Clark PI, Langley RE (2009) Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 27(30): 5062-5067
2. Astanehe A, Finkbeiner MR, Hojabrpour P, To K, Fotovati A, Shadeo A, Stratford AL, Lam WL, Berquin IM, Duronio V, Dunn SE (2009) The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1. Oncogene 28(25): 2406-2418
3. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dorken B, Royer HD (1997) Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 3(4): 447-450 (Pubitemid 27145688)
4. Berquin IM, Pang B, Dziubinski ML, Scott LM, Chen YQ, Nolan GP, Ethier SP (2005) Y-box-binding protein 1, confers EGF independence to human mammary epithelial cells. Oncogene 24(19): 3177-3186 (Pubitemid 40695086)
5. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6): 567-578 (Pubitemid 43209104)
6. Bozec A, Gros FX, Penault-Llorca F, Formento P, Cayre A, Dental C, Etienne-Grimaldi MC, Fischel JL, Milano G (2008) Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition. Eur J Cancer 44(13): 1922-1930
7. Bryne M, Koppang HS, Lilleng R, Kjaerheim A (1992) Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. J Pathol 166(4): 375-381
8. Chang SS, Califano J (2008) Current status of biomarkers in head and neck cancer. J Surg Oncol 97(8): 640-643 (Pubitemid 351812962)
9. Chin D, Boyle GM, Williams RM, Ferguson K, Pandeya N, Pedley J, Campbell CM, Theile DR, Parsons PG, Coman WB (2005) Novel markers for poor prognosis in head and neck cancer. Int J Cancer 113(5): 789-797 (Pubitemid 40101261)
10. Chung CH, Parker JS, Ely K, Carter J, Yi Y, Murphy BA, Ang KK, El-Naggar AK, Zanation AM, Cmelak AJ, Levy S, Slebos RJ, Yarbrough WG (2006) Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 66(16): 8210-8218 (Pubitemid 44299189)
11. Coles LS, Lambrusco L, Burrows J, Hunter J, Diamond P, Bert AG, Vadas MA, Goodall GJ (2005) Phosphorylation of cold shock domain/Y-box proteins by ERK2 and GSK3beta and repression of the human VEGF promoter. FEBS Lett 579(24): 5372-5378 (Pubitemid 41395158)
12. Conley BA (2006) Treatment of advanced head and neck cancer: what lessons have we learned? J Clin Oncol 24(7): 1023-1025 (Pubitemid 46638795)
13. Das S, Chattopadhyay R, Bhakat KK, Boldogh I, Kohno K, Prasad R, Wilson SH, Hazra TK (2007) Stimulation of NEIL2-mediated oxidized base excision repair via YB-1 interaction during oxidative stress. J Biol Chem 282(39): 28474-28484 (Pubitemid 47606000)
14. Dhillon J, Astanehe A, Lee C, Fotovati A, Hu K, Dunn SE (2010) The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44(+) cells. Oncogene 29(47): 6294-6300
15. Evdokimova V, Ruzanov P, Imataka H, Raught B, Svitkin Y, Ovchinnikov LP, Sonenberg N (2001) The major mRNA-associated protein YB-1 is a potent 50 cap-dependent mRNA stabilizer. EMBO J 20(19): 5491-5502 (Pubitemid 32959469)
16. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, Sorokin A, Ovchinnikov LP, Davicioni E, Triche TJ, Sorensen PH (2009) Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 15(5): 402-415
17. Finkbeiner MR, Astanehe A, To K, Fotovati A, Davies AH, Zhao Y, Jiang H, Stratford AL, Shadeo A, Boccaccio C, Comoglio P, Mertens PR, Eirew P, Raouf A, Eaves CJ, Dunn SE (2009) Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene 28(11): 1421-1431
18. Forastiere A, Koch W, Trotti A, Sidransky D (2001) Head and neck cancer. N Engl J Med 345(26): 1890-1900 (Pubitemid 33716564)
19. Gaudreault I, Guay D, Lebel M (2004) YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities and binds several DNA repair proteins. Nucleic Acids Res 32(1): 316-327 (Pubitemid 38228631)
20. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Ettinger S, Gleave ME, Nelson CC (2004) YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 59(3): 337-349 (Pubitemid 38509767)
21. Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, Pambuccian SE, Ondrey FG, Adams GL, Gaffney PM (2004) Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 64(1): 55-63 (Pubitemid 38114082)
22. Gluz O, Mengele K, Schmitt M, Kates R, Diallo-Danebrock R, Neff F, Royer HD, Eckstein N, Mohrmann S, Ting E, Kiechle M, Poremba C, Nitz U, Harbeck N (2009) Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. J Clin Oncol 27(36): 6144-6145
23. Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE (2008) Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and diseasespecific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 10(5): R86
24. Haddad RI Shin DM (2008) Recent advances in head and neck cancer. N Engl J Med 359(11): 1143-1154
25. Hall SF, Groome PA, Irish J, Sullivan B (2009) TNM-based stage groupings in head and neck cancer: application in cancer of the hypopharynx. Head Neck 31(1): 1-8
26. Holzmuller R, Mantwill K, Haczek C, Rognoni E, Anton M, Kasajima A, Weichert W, Treue D, Lage H, Schuster T, Schlegel J, Gansbacher B, Holm PS (2011) YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma. Int J Cancer 129(5): 1265-1276
27. Huang CH, Yang WH, Chang SY, Tai SK, Tzeng CH, Kao JY, Wu KJ, Yang MH (2009) Regulation of membrane-type 4 matrix metalloproteinase by SLUG contributes to hypoxia-mediated metastasis. Neoplasia (New York, NY 11(12): 1371-1382
28. Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Kolk A, Pautke C, Horch HH (2005) Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity-clinical relevance and prognostic value. J Craniomaxillofac Surg 33(3): 191-196 (Pubitemid 40614180)
29. Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jurchott K, Schmitt M, Royer HD (2002) Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Inte J Cancer 97(3): 278-282 (Pubitemid 34049016)
30. Jethwa P, Naqvi M, Hardy RG, Hotchin NA, Roberts S, Spychal R, Tselepis C (2008) Overexpression of Slug is associated with malignant progression of esophageal adenocarcinoma. World J Gastroenterol 14(7): 1044-1052 (Pubitemid 351325004)
31. Jurchott K, Bergmann S, Stein U, Walther W, Janz M, Manni I, Piaggio G, Fietze E, Dietel M, Royer HD (2003) YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem 278(30): 27988-27996 (Pubitemid 36899994)
32. Kamura T, Yahata H, Amada S, Ogawa S, Sonoda T, Kobayashi H, Mitsumoto M, Kohno K, Kuwano M, Nakano H (1999) Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer 85(11): 2450-2454 (Pubitemid 29244855)
33. Kashihara M, Azuma K, Kawahara A, Basaki Y, Hattori S, Yanagawa T, Terazaki Y, Takamori S, Shirouzu K, Aizawa H, Nakano K, Kage M, Kuwano M, Ono M (2009) Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer. J Thorac Oncol 4(9): 1066-1074
34. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M (2003) The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 25(7): 691-698 (Pubitemid 36850797)
35. Kuwano M, Oda Y, Izumi H, Yang SJ, Uchiumi T, Iwamoto Y, Toi M, Fujii T, Yamana H, Kinoshita H, Kamura T, Tsuneyoshi M, Yasumoto K, Kohno K (2004) The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther 3(11): 1485-1492 (Pubitemid 39562593)
36. Kuwano M, Uchiumi T, Hayakawa H, Ono M, Wada M, Izumi H, Kohno K (2003) The basic and clinical implications of ABC transporters, Y-boxbinding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci 94(1): 9-14 (Pubitemid 36575851)
37. Langer R, Von Rahden BH, Nahrig J, Von Weyhern C, Reiter R, Feith M, Stein HJ, Siewert JR, Hofler H, Sarbia M (2006) Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol 59(6): 631-634 (Pubitemid 43886048)
38. Lee C, Dhillon J, Wang MY, Gao Y, Hu K, Park E, Astanehe A, Hung MC, Eirew P, Eaves CJ, Dunn SE (2008) Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res 68(21): 8661-8666
39. Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F, Chen ZQ, Liu XP, Xu ZD (2009) Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 15(8): 2657-2665
40. Ludwig JA, Weinstein JN (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5(11): 845-856 (Pubitemid 41746029)
41. Masuda M, Wakasaki T, Suzui M, Toh S, Joe AK, Weinstein IB (2010) Stat3 orchestrates tumor development and progression: the Achilles0 heel of head and neck cancers? Curr Cancer Drug Targets 10(1): 117-126
42. Mertens PR, Harendza S, Pollock AS, Lovett DH (1997) Glomerular mesangial cell-specific transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1. J Biol Chem 272(36): 22905-22912 (Pubitemid 27386113)
43. Mucke T, Wagenpfeil S, Kesting MR, Holzle F, Wolff KD (2009) Recurrence interval affects survival after local relapse of oral cancer. Oral Oncol 45(8): 687-691
44. Oda Y, Ohishi Y, Saito T, Hinoshita E, Uchiumi T, Kinukawa N, Iwamoto Y, Kohno K, Kuwano M, Tsuneyoshi M (2003) Nuclear expression of Y-boxbinding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J Pathol 199(2): 251-258 (Pubitemid 36176032)
45. Oda Y, Sakamoto A, Shinohara N, Ohga T, Uchiumi T, Kohno K, Tsuneyoshi M, Kuwano M, Iwamoto Y (1998) Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res 4(9): 2273-2277 (Pubitemid 28415677)
46. Pham CG, Bubici C, Zazzeroni F, Knabb JR, Papa S, Kuntzen C, Franzoso G (2007) Upregulation of Twist-1 by NF-kappaB blocks cytotoxicity induced by chemotherapeutic drugs. Mol Cell Biol 27(11): 3920-3935 (Pubitemid 47010991)
47. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104(3): 973-978 (Pubitemid 46154721)
48. Robbins KT, Shaha AR, Medina JE, Califano JA, Wolf GT, Ferlito A, Som PM, Day TA (2008) Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg 134(5): 536-538 (Pubitemid 351724386)
49. Rogers SN, Brown JS, Woolgar JA, Lowe D, Magennis P, Shaw RJ, Sutton D, Errington D, Vaughan D (2009) Survival following primary surgery for oral cancer. Oral Oncol 45(3): 201-211
50. Schittek B, Psenner K, Sauer B, Meier F, Iftner T, Garbe C (2007) The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer 120(10): 2110-2118 (Pubitemid 46555847)
51. Shah NG, Trivedi TI, Tankshali RA, Goswami JA, Jetly DH, Kobawala TP, Shukla SN, Shah PM, Verma RJ (2006) Stat3 expression in oral squamous cell carcinoma: association with clinicopathological parameters and survival. Int J Biol Markers 21(3): 175-183 (Pubitemid 44660290)
52. Shah NG, Trivedi TI, Tankshali RA, Goswami JV, Jetly DH, Shukla SN, Shah PM, Verma RJ (2009) Prognostic significance of molecular markers in oral squamous cell carcinoma: a multivariate analysis. Head Neck 31(12): 1544-1556
53. Sherry MM, Reeves A, Wu JK, Cochran BH (2009) STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem cells (Dayton, Ohio) 27(10): 2383-2392
54. Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K, Yasumoto K, Sugimachi K, Kuwano M (2001) Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 7(10): 3151-3155 (Pubitemid 32963838)
55. Shiota M, Izumi H, Tanimoto A, Takahashi M, Miyamoto N, Kashiwagi E, Kidani A, Hirano G, Masubuchi D, Fukunaka Y, Yasuniwa Y, Naito S, Nishizawa S, Sasaguri Y, Kohno K (2009) Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res 69(7): 3148-3156
56. Stickeler E, Fraser SD, Honig A, Chen AL, Berget SM, Cooper TA (2001) The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4. EMBO J 20(14): 3821-3830 (Pubitemid 32691793)
57. Stratford AL, Habibi G, Astanehe A, Jiang H, Hu K, Park E, Shadeo A, Buys TP, Lam W, Pugh T, Marra M, Nielsen TO, Klinge U, Mertens PR, Aparicio S, Dunn SE (2007) Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res 9(5): R61
58. Sturgis EM Wei Q, Spitz MR (2004) Descriptive epidemiology and risk factors for head and neck cancer. Semin Oncol 31(6): 726-733 (Pubitemid 39602678)
59. Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M, Leighton Grimes H, Miller K, Badve S, Huntsman D, Blake-Gilks C, Chen M, Pallen CJ, Dunn SE (2005) Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24(26): 4281-4292 (Pubitemid 40961781)
60. Tay WL, Yip GW, Tan PH, Matsumoto K, Yeo R, Ng TP, Kumar SD, Tsujimoto M, Bay BH (2009) Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer. Mod Pathol 22(2): 282-290
61. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R (2008) Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26(7): 1086-1092
62. To K, Fotovati A, Reipas KM, Law JH, Hu K,Wang J, Astanehe A, Davies AH, Lee L, Stratford AL, Raouf A, Johnson P, Berquin IM, Royer HD, Eaves CJ, Dunn SE (2010) Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res 70(7): 2840-2851
63. Wu J, Stratford AL, Astanehe A, Dunn SE (2007) YB-1 is a transcription/translation factor that orchestrates the oncogenome by hardwiring signal transduction to gene expression. Transl Oncogen 2007: 249-265
64. Xie F, Li K, Ouyang X (2009) Twist, an independent prognostic marker for predicting distant metastasis and survival rates of esophageal squamous cell carcinoma patients. Clin Exp Metastasis 26(8): 1025-1032
65. Xu W, Zhou L, Qin R, Tang H, Shen H (2009) Nuclear expression of YB-1 in diffuse large B-cell lymphoma: correlation with disease activity and patient outcome. Eur J Haematol 83(4): 313-319
66. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117(7): 927-939 (Pubitemid 38798858)